drugset / Trial / NCT01234870
Comprehensive Evaluation of Ischemic Heart Disease Using MRI
Phase 2/3
Completed
40 enrolled
Northwestern University
Astellas Pharma US, Inc. · collabBayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma · collab
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of the study is to assess the diagnostic performance of fully automated motion corrected (MC) first pass myocardial perfusion MRI, compared to the original non-corrected first pass myocardial perfusion images in a cohort of patients with suspected ischemic heart disease, using coronary angiography as the reference standard. It is expected that this improved comprehensive protocol for cardiac MRI be accurate at detecting significant coronary artery disease and may obviate the need for other more expensive and invasive diagnostic tests currently used.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Adenosine | Small molecule | 0.14 unknown | — |
| Background | Gadolinium | Diagnostic / imaging agent | 0.075 unknown | Other |